secwatch.observer — SEC 8-K summary
======================================

Issuer:     GENELUX Corp (GNLX)
CIK:        0001231457
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001641172-25-000528
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).
- Phase 1b/2 SCLC data: 71% disease control rate among 7 evaluable patients; 2 partial responses; 79% tumor reduction in one.
- FDA Type D meeting for Olvi-Vec in PRROC: FDA indicated clinically meaningful PFS advantage without OS decrement could support traditional approval; pre-BLA meeting recommended.
- Anticipates reporting Phase 3 topline (OnPrime/GOG-3076) in H1 2026 and Phase 2 VIRO-25 interim in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/0001641172-25-000528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer